Collaboration Opportunities with Daiichi Sankyo in Early Stage Research and Technology


One Nucleus is delighted to be working with Daiichi Sankyo and the Department for International Trade Japan Team to bring you a free online seminar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. 

Dates Thursday, October 1, 2020 - Download as vCalendar
Event Times: 10:00 to 11:00
Venue Online
Email info@onenucleus.com
Website Event website

Event details:

Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas. One Nucleus is delighted to be working with Daiichi Sankyo and the Department for International Trade Japan Team to bring you a free online seminar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:

  • Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
    • Ex) Target protein degrader (except E3 binder), conditional active antibody (except pH-dependent), next generation of gene therapy etc
  • Novel drug delivery technologies to cancer cells or brain after systemic administration
    • Ex) Engineered nanoparticle/exosome etc
  • Novel target or cancer-specific antigen for antibody in oncology

One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.